A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lee, Jung Sun ^a   Hur, Man Wook ^b   Lee, Seong Kyung ^a   Choi, Won Il ^a,b   Kwon, Young Guen ^c   Yun, Chae Ok ^d  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA CATENIN; CASPASE 3; CYTOCHROME C; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; PHOSPHATIDYLINOSITOL 3 KINASE; SOLUBLE LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6 E1 AND E2 REGION; UNCLASSIFIED DRUG; WNT3A PROTEIN; CTNNB1 PROTEIN, HUMAN; FRIZZLED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LRP6 PROTEIN, HUMAN; SMALL INTERFERING RNA; T CELL FACTOR PROTEIN; WNT3A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INDUCTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MARKER GENE; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STABILITY; UPREGULATION; VIRUS REPLICATION; WNT SIGNALING PATHWAY; ANIMAL; DRUG ANTAGONISM; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; LUNG TUMOR; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE;

ADENOVIRUSES, HUMAN; ANIMALS; APOPTOSIS; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE THERAPY; GENETIC VECTORS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASM INVASIVENESS; RECEPTORS, WNT; RNA, SMALL INTERFERING; TCF TRANSCRIPTION FACTORS; WNT SIGNALING PATHWAY; WNT3A PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861007025     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036520     Document Type: Article

References (43)

1. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC, (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340: 1733-1739.
2. Broxterman HJ, Georgopapadakou NH, (2007) Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma. Drug Resist Updat 10: 182-193.
3. Liu JR, Opipari AW, Tan L, Jiang Y, Zhang Y, et al. (2002) Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res 62: 924-931.
4. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, et al. (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 14: 497-502.
5. Nishio M, Koshikawa T, Yatabe Y, Kuroishi T, Suyama M, et al. (1997) Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 3: 1051-1058.
6. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23: 2513-2520.
7. Nusse R, Theunissen H, Wagenaar E, Rijsewijk F, Gennissen A, et al. (1990) The Wnt-1 (int-1) oncogene promoter and its mechanism of activation by insertion of proviral DNA of the mouse mammary tumor virus. Mol Cell Biol 10: 4170-4179.
8. Beachy PA, Karhadkar SS, Berman DM, (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432: 324-331.
9. Holcombe RF, Marsh JL, Waterman ML, Lin F, Milovanovic T, et al. (2002) Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55: 220-226.
10. DeAlmeida VI, Miao L, Ernst JA, Koeppen H, Polakis P, et al. (2007) The soluble wnt receptor Frizzled8CRD-hFc inhibits the growth of teratocarcinomas in vivo. Cancer Res 67: 5371-5379.
11. Li Y, Lu W, He X, Schwartz AL, Bu G, (2004) LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 23: 9129-9135.
12. Liu CC, Pearson C, Bu G, (2009) Cooperative folding and ligand-binding properties of LRP6 beta-propeller domains. J Biol Chem 284: 15299-15307.
13. He X, Semenov M, Tamai K, Zeng X, (2004) LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 131: 1663-1677.
14. Zhang Y, Wang Y, Li X, Zhang J, Mao J, et al. (2004) The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 24: 4677-4684.
15. Forrester WC, (2002) The Ror receptor tyrosine kinase family. Cell Mol Life Sci 59: 83-96.
16. Signorello LB, Cohen SS, Bosetti C, Stovall M, Kasper CE, et al. (2006) Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst 98: 1453-1461.
17. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, et al. (2007) VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15: 295-302.
18. Yoon AR, Kim JH, Lee YS, Kim H, Yoo JY, et al. (2006) Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 17: 379-390.
19. Kim J, Kim JH, Choi KJ, Kim PH, Yun CO, (2007) E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther 18: 773-786.
20. Lou Z, Chini CC, Minter-Dykhouse K, Chen J, (2003) Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem 278: 13599-13602.
21. Yun CO, Kim E, Koo T, Kim H, Lee YS, et al. (2005) ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 12: 61-71.
22. Yoo JY, Kim JH, Kim J, Huang JH, Zhang SN, et al. (2008) Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 15: 635-651.
23. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
24. Yun MS, Kim SE, Jeon SH, Lee JS, Choi KY, (2005) Both ERK and Wnt/beta-catenin pathways are involved in Wnt3a-induced proliferation. J Cell Sci 118: 313-322.
25. Kim SE, Lee WJ, Choi KY, (2007) The PI3 kinase-Akt pathway mediates Wnt3a-induced proliferation. Cell Signal 19: 511-518.
26. Grotewold L, Ruther U, (2002) The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 21: 966-975.
27. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, et al. (2003) Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res 63: 831-837.
28. Gupta GP, Massague J, (2006) Cancer metastasis: building a framework. Cell 127: 679-695.
29. Yang J, Weinberg RA, (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829.
30. Wu B, Crampton SP, Hughes CC, (2007) Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26: 227-239.
31. Bjornland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, et al. (2005) Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res 127: 151-156.
32. Uematsu K, He B, You L, Xu Z, McCormick F, et al. (2003) Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22: 7218-7221.
33. He B, You L, Uematsu K, Xu Z, Lee AY, et al. (2004) A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6: 7-14.
34. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64: 5385-5389.
35. Vincan E, Darcy PK, Smyth MJ, Thompson EW, Thomas RJ, et al. (2005) Frizzled-7 receptor ectodomain expression in a colon cancer cell line induces morphological change and attenuates tumor growth. Differentiation 73: 142-153.
36. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, et al. (2005) Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65: 9762-9770.
37. Dennis S, Aikawa M, Szeto W, d'Amore PA, Papkoff J, (1999) A secreted frizzled related protein, FrzA, selectively associates with Wnt-1 protein and regulates wnt-1 signaling. J Cell Sci 112 (Pt 21): 3815-3820.
38. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, et al. (2004) Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 101: 3118-3123.
39. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C, (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998.
40. Kurihara T, Brough DE, Kovesdi I, Kufe DW, (2000) Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 106: 763-771.
41. Zhou Z, Zhou RR, Guan H, Bucana CD, Kleinerman ES, (2003) E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Mol Cancer Ther 2: 1313-1319.
42. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, et al. (2006) Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 13: 242-252.
43. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, et al. (1992) Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7: 77-83.